Blafarm, I really wonder about dosage and timing of doses too.
First of all, if we are treating S/C, we should dose as Lalezari suggested - intravenously for first dose. Perhaps a week late, 350ml, and a week later, another 350mls.
Pourhassen has said we get 100% CCR5 occupancy with the first dose, even subcutaneously. But if we want better results, the drug should be put into a person's system faster. Occupancy of CCR5 receptors lasts for at least 60 days but new receptors after dosing will appear and not be blockaded. So, another dose a week later for those receptors. A week later, perhaps another dose.
Those later doses wouldn't need to be as strong as the first one it seems to me but prolonged dosing might be a very good thing.
If considerations like this are proven out later, what do you have to do to change the treatment protocols? Lalezari would know. I think I might try to ask him. We haven't heard from him lately and I would really like to hear him weigh in on issues like this and whatever he thinks is important as things have gone along.
I suspect dosage and timing will be quite important in long-haulers. Without adjustments there, Leronlimab may be wasted and effects on symptoms may be less than optimal. Things to consider on our path to approval.
First of all, if we are treating S/C, we should dose as Lalezari suggested - intravenously for first dose. Perhaps a week late, 350ml, and a week later, another 350mls.
Pourhassen has said we get 100% CCR5 occupancy with the first dose, even subcutaneously. But if we want better results, the drug should be put into a person's system faster. Occupancy of CCR5 receptors lasts for at least 60 days but new receptors after dosing will appear and not be blockaded. So, another dose a week later for those receptors. A week later, perhaps another dose.
Those later doses wouldn't need to be as strong as the first one it seems to me but prolonged dosing might be a very good thing.
If considerations like this are proven out later, what do you have to do to change the treatment protocols? Lalezari would know. I think I might try to ask him. We haven't heard from him lately and I would really like to hear him weigh in on issues like this and whatever he thinks is important as things have gone along.
I suspect dosage and timing will be quite important in long-haulers. Without adjustments there, Leronlimab may be wasted and effects on symptoms may be less than optimal. Things to consider on our path to approval.
7
